mbb 304 q5

Gene Editing (CRISPR-Cas9)

A precision gene therapy approach using tools like CRISPR-Cas9 to directly cut, repair, or rewrite target DNA sequences. Unlike gene replacement, it alters existing genomic sequences [1, 2].

Casgevy

A CRISPR-Cas9-based gene-editing therapeutic that modifies cellular genetics without restoring the wildtype sequence of the β-globin gene, illustrating the diversity of editing mechanisms [2, 3].

Embryo vs. Adult Gene Editing

Editing is more effective at the fertilized egg stage because modifying a single cell alters all future cells in the organism, whereas editing a full-grown human requires delivering tools to trillions of cells (though embryo editing raises major ethical concerns) [3].

Electroporation in Gene Therapy

A physical delivery method (used in Casgevy) applying short, high-voltage electrical pulses to transiently increase cell membrane permeability, enabling Cas9 protein, guide RNA, and repair templates to enter target cells [3].

Viral Vector Delivery of CRISPR

Delivery where viral genomes (e.g., AAV or lentivirus) encode Cas9 mRNA and guide RNA. Target cells transcribe and translate the CRISPR machinery prior to editing, limited mainly by packaging capacity constraints [3].

Lipid Nanoparticles (LNPs)

Artificial specialized lipid delivery systems (pioneered by Prof. Pieter Cullis) used to safely package and transport nucleic acid payloads (mRNA, siRNA, DNA) into target cells while protecting them from degradation [4].

LNP Mechanism & Endosomal Escape

LNPs enter cells via endocytosis; as the endosome acidifies, ionizable lipids become protonated and destabilize the endosomal membrane, releasing the nucleic acid payload into the cytoplasm [4].

Antisense Oligonucleotides (ASOs)

Short, synthetic single-stranded nucleic-acid sequences designed to hybridize with specific target RNA sequences to alter RNA processing, splicing, or protein translation [5].

ASO Mechanism: RNase H1 Degradation

ASO binding to target mRNA forms an RNA-DNA hybrid that recruits RNase H1 enzyme, which cleaves the target RNA strand and achieves gene knockdown [5].

ASO Mechanism: Steric Blockade

ASO binding physically sits on target mRNA to block ribosomes or cellular machinery from scanning and translating the transcript, impairing protein translation without degrading the RNA [5].

ASO Mechanism: Splice Site-Modulation

ASO binding to pre-mRNA splice regulatory sites blocks spliceosome access, promoting either exon skipping or exon inclusion depending on nucleotide design and target site location [6].

Progeria Splicing Defect

Hutchinson-Gilford Progeria Syndrome is caused by a point mutation (LMNA c.1824C>T, p.G608G) creating a cryptic splice site in exon 11, resulting in a 150-bp deletion and production of toxic Progerin protein [6, 7].

Progerin-Specific ASO

A synthetic ASO (3'-GGTCCACCCACCTGGGTAGA-5') engineered to specifically hybridize to the cryptic splice site on LMNA pre-mRNA, blocking aberrant splicing and restoring normal Prelamin A processing [6, 7].

Therapeutic Delivery Considerations

Gene therapy design requires selecting strategy (replacement/editing/silencing/ASO), delivery approach (in vivo vs. ex vivo), delivery vector (AAV, lentivirus, LNP, electroporation), and target cell type based on disease pathobiology [8-10].

Monogenic Disorders

Diseases caused by mutations in a single gene (e.g., Cystic Fibrosis, Progeria); cell biology is generally simpler to understand as only one gene is primarily dysregulated [11].

Chromosomal Abnormalities

Genetic disorders caused by duplication, deletion, or rearrangement of whole chromosomes or chromosome segments, affecting multiple genes simultaneously and causing complex cellular dysregulation [11, 12].

Multifactorial Disorders

Complex diseases involving interactions among multiple genes, environmental factors, and lifestyle choices without Mendelian inheritance patterns (e.g., Diabetes, Cancer, Infertility, PMOS) [11, 13, 14].

Euploidy vs. Aneuploidy

Euploidy refers to a chromosome number that is an exact multiple of the haploid set (n, 2n, 3n). Aneuploidy refers to an abnormal chromosome number that is not an exact multiple (e.g., 2n+1 or 2n-1) [15].

Trisomy vs. Monosomy

Trisomy is an aneuploid condition with three copies of a specific chromosome in a cell (2n+1). Monosomy is the presence of only one copy of a specific chromosome (2n-1) [15].

Types of Structural Chromosomal Abnormalities

Deletions (missing segment), Duplications (copied segment), Translocations (segment swapped between chromosomes), and Inversions (segment orientation reversed) [16].

Robertsonian Translocation

A specific chromosomal rearrangement where the long arms of two acrocentric chromosomes (such as 13 and 14, or 14 and 21) fuse at the centromere, losing the short arms [16-18].

Examples of Aneuploid Syndromes

Down Syndrome (Trisomy 21), Patau Syndrome (Trisomy 13), Edwards Syndrome (Trisomy 18), and Klinefelter Syndrome (47, XXY) [15, 16, 19].

Down Syndrome Organismal Features

Aneuploid condition (47 chromosomes, Trisomy 21) with ~1 in 700 US live births and ~60 yr life expectancy; features include broad flat face, slanting eyes, epicanthic folds, single palmar crease, hypotonia, and congenital heart disease [19, 20].

Mitotic vs. Meiotic Chromosomal Errors

Mitotic errors occur in somatic division, affecting sub-populations of cells in an organism without being passed to offspring. Meiotic errors occur during gametogenesis, affecting every cell of the resulting offspring [21].

Non-Disjunction Definition

The failure of homologous chromosomes or sister chromatids to separate properly during anaphase of cell division, resulting in daughter cell aneuploidy [21, 22].

Non-Disjunction Timing & Gamete Outcomes

Non-disjunction in Meiosis I produces 100% aneuploid gametes (2 disomic, 2 nullisomic). Non-disjunction in Meiosis II produces 50% normal haploid gametes, 25% disomic, and 25% nullisomic [22].

Parent of Origin in Down Syndrome

Non-disjunction causing Down Syndrome originates from maternal meiosis in ~90% of cases and paternal meiosis in ~10% of cases [22].

Maternal Age Effect on Down Syndrome

Frequency of Down Syndrome increases exponentially with maternal age (0.05% at age 20, 0.29% at 35, 1.00% at 40, 3.33% at 45, and 10.0% at 49), while paternal age shows minimal effect [22, 23].

Oogenesis Pauses & Age-Related Nondisjunction

Female primary oocytes pause in Meiosis I (Prophase I) from the 5th fetal month until ovulation (up to 50 years later) and in Metaphase II until fertilization. Long arrest leads to age-related degradation of spindle and meiotic machinery [24-27].

Chromosome 21 Structure & p-Arm Function

Chromosome 21 contains ~48 Mb. The short (p) arm of acrocentric chr 21 encodes rRNA genes (nucleolar organizing region); because 200-400 rRNA copies exist across acrocentrics (13,14,15,21,22), p-arm loss is fully compensated [17, 18].

Chromosome 21 q-Arm

Encodes ~250 genes (~90 of unknown function). Translocation of the q-arm onto chromosome 14 (Robertsonian translocation) is sufficient to cause Down Syndrome [17, 18].

Mouse Models of Down Syndrome (Ts65Dn)

Human Chr 21 q-arm genes map to mouse Chr 10, 16, and 17. The Ts65Dn mouse model (partial trisomy of Chr 16 carrying 132 genes) best phenocopies human Down syndrome traits [28, 29].

Gene Dosage Effect Hypothesis

Proposes that Down syndrome phenotypes result from the cumulative increased gene dosage (150% expression) of unmutated wildtype genes on chromosome 21 [20, 30].

Identical Twin Model for Down Syndrome

Letourneau et al. studied monozygotic twins discordant for Trisomy 21, revealing domain-wide gene expression dysregulation (Lamina-Associated Domains / LADs) across the entire genome, altering nuclear organization [31, 32].

APP (Amyloid Precursor Protein)

Gene on Chr 21 overexpressed in Down Syndrome; involved in membrane signaling and closely linked to early-onset Alzheimer's disease pathology [33].

SOD1 (Superoxide Dismutase 1)

Gene on Chr 21 whose overexpression contributes to increased oxidative stress and neurodegeneration (notably linked to ALS) [33].

OLIG1 (Oligodendrocyte Transcription Factor 1)

Transcription factor on Chr 21 that acts as a repressor/calibrator of neurogenesis; elevated dosage disrupts normal neuronal differentiation [33].

ETS2 Transcription Factor

Gene on Chr 21 expressed in skin and bone regulating proliferation and differentiation; overexpression is linked to hallmark Down syndrome craniofacial alterations [33].

COL6A1 (Collagen Alpha-1 VI Chain)

Extracellular collagen gene on Chr 21 expressed in muscle; over-expression is associated with hypertension and congenital heart defects [34].

DYRK1A Kinase ("Goldilocks Kinase")

Dual-specificity kinase on Chr 21 regulating neurogenesis, angiogenesis, and proliferation; dosage-sensitive regulator requiring strict physiological control [34-36].

DYRK1A Over-expression vs. Haploinsufficiency

150% dosage (Trisomy 21) causes impaired neurogenesis, heart defects, leukemia, and Alzheimer's. 50% dosage (DYRK1A syndrome) causes microcephaly, autism spectrum disorder, seizures, and intellectual disability [35, 36].

Haplosufficiency

Genetic phenomenon where one functional allele (50% dosage) is sufficient to maintain a normal wildtype phenotype (typical for autosomal recessive carriers) [37-39].

Haploinsufficiency

Genetic phenomenon where a single functional allele (50% dosage) is NOT sufficient to produce a normal phenotype, resulting in an autosomal dominant disease [36-38].

Dominant Negative Mutation

A mutation where the altered gene product is non-functional AND actively interferes with/inhibits the function of the co-expressed wildtype protein [37, 38].

Beta-Thalassemia & Dosage Sensitivity

Clinical severity correlates with beta-globin active product levels: Beta Trait (minor/no symptoms, beta/beta+ or beta/beta0), Beta Intermedia (moderate symptoms, beta+/beta0), Beta Major (severe symptoms, beta0/beta0) [39, 40].

Nuchal Translucency Scan

Prenatal screening ultrasound performed at 11-14 weeks measuring fluid accumulation at the back of the fetal neck to screen for Down syndrome craniofacial/cardiac anomalies [40, 41].

Karyotyping Protocol

Diagnostic procedure: culture peripheral blood lymphocytes for 72h, add mitotic inhibitor (colchicine) to arrest in metaphase, apply hypotonic KCl shock to swell cells, fix with acetic acid/methanol, drop on slide, stain, and analyze [41, 42].

Giemsa Banding (G-Banding vs. R-Banding)

G-Banding stains AT-rich DNA dark. R-Banding heats samples prior to Giemsa staining, causing GC-rich DNA regions to stain dark instead [43].

Embryonic Lethality & Miscarriage Statistics

50-75% of pregnancies terminate prior to week 3 implantation; ~90% of first-trimester miscarriages result from lethal chromosomal abnormalities [13, 44].

Miscarriage Incidence Rates

10-20% of clinically recognized pregnancies end in miscarriage; overall total pregnancy loss may reach up to 50% [13].

Etiology of Multifactorial Disorders

Disease development driven by complex interactions between polygenic susceptibility variants, intrinsic biology, extrinsic environmental factors, and lifestyle choices [13, 14].

Clinical Themes of Multifactorial Inheritance

Genetic predisposition, variable age of onset, gradual progressive decline, variable severity, and absence of classic Mendelian (dominant/recessive) pedigree patterns [14].

Global Infertility Prevalence

Infertility affects approximately 13-15% of reproductive-age couples globally after one year of attempting conception without success [45, 46].

Distribution of Infertility Etiology

Infertility causes are attributed to Male factors (~30%), Female factors (~30%), Combined male+female factors (~20%), and Unexplained factors (~20%) [46].

Unique Feature of Infertility Etiology

Infertility is a medical condition where the primary underlying biological etiology can be located entirely within a different individual (the partner) [46].

Semen Analysis Reference Parameters

Normal semen parameters: Sperm concentration >15 million/mL, Total semen volume >1.5 mL, Sperm motility >32% motile, Normal morphology >14% normal forms [47].

Oligozoospermia vs. Azoospermia

Oligozoospermia is a reduced sperm concentration (<15 million sperm/mL). Azoospermia is the complete absence of sperm in ejaculated semen [47, 48].

Global Sperm Count Decline

Longitudinal studies demonstrate western/global average sperm counts declined by over 50% between 1973 (101 million/mL) and 2018 (49 million/mL) [47].

Phases of Spermatogenesis

Occurs continuously in seminiferous tubules: Mitosis (spermatogonia renewal), Meiosis I & II (crossover & haploid spermatid formation), and Spermiogenesis (structural differentiation into motile spermatozoa) [48].

Temperature Sensitivity of Spermatogenesis

Mammalian spermatogenesis requires ~34°C (scrotal temp). Exposure to 37°C disrupts meiotic crossover; 38°C causes double-strand DNA breaks and meiotic prophase I failure [49].

Extrinsic Thermal Infertility

Environmental heat exposure (e.g., repeated hot tub use or laptop placement) can temporarily suppress sperm count to zero, taking up to 6 months to recover after heat removal [50].

Globozoospermia

A monogenic male infertility disorder caused by DPY19L2 gene mutations leading to round, acrosome-less sperm unable to penetrate the oocyte zona pellucida [51].

Primary Ciliary Dyskinesia (PCD) Infertility

Mutations in axonemal dynein genes (e.g., DNAH5, DNAI1/2, DNAAF1-3) impair sperm tail flagellar beating, causing asthenozoospermia (immotile sperm) [51].

Cystic Fibrosis & Male Infertility

~98% of males with Cystic Fibrosis (CFTR mutations) are infertile due to congenital bilateral absence/blockage of the vas deferens, producing obstructive azoospermia [52].

Complexity of Female Infertility

Female reproductive function requires coordinate execution of oogenesis, follicular maturation, ovulation, sperm reception, endometrial preparation, implantation, and gestation [53, 54].

Polyendocrine Metabolic Ovarian Syndrome (PMOS / PCOS)

A common multifactorial endocrine/metabolic disorder affecting 5-20% of reproductive-age women, characterized by hyperandrogenism, ovulatory dysfunction, and insulin resistance [55, 56].